CureVac N.V. - Ordinary Shares (CVAC) Covered Calls
You can sell covered calls on CureVac N.V. - Ordinary Shares to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for CVAC (prices last updated Fri 4:16 PM ET):
| CureVac N.V. - Ordinary Shares (CVAC) Stock Quote | ||||||
|---|---|---|---|---|---|---|
| Last | Change | Bid | Ask | Volume | P/E | Market Cap |
| 4.10 | -0.08 | 4.10 | 4.25 | 588K | - | 0.8 |
| Covered Calls For CureVac N.V. - Ordinary Shares (CVAC) | ||||||
|---|---|---|---|---|---|---|
| Expiration | Strike | Call Bid | Net Debit | Return If Flat |
Annualized Return If Flat |
|
| Feb 21 | 4 | 0.00 | 4.25 | -5.9% | -59.8% | |
| Mar 21 | 4 | 0.00 | 4.25 | -5.9% | -33.6% | |
| Subscribers get access to the full covered call chain, and more features. | ||||||
Want to make money with covered calls? Sign Up For A Free Trial
Extended Business Description
CureVac N.V., a clinical-stage biopharmaceutical company, engages in developing various transformative medicines based on messenger ribonucleic acid (mRNA). Its lead proprietary programs include CV8102 that is in a Phase 1 dose escalating clinical trials for four types of cancers as a monotherapy and in combination with anti-PD-1; and CV7202, which is in a Phase 1 clinical trials as a vaccine candidate against rabies. It is also advancing mRNA vaccine program against coronavirus (SARS-CoV-2), which is in Phase 1 clinical trial. The company's partnered programs comprise BI1361849, a therapeutic vaccine candidate that is in a Phase 1/2 clinical trials to elicit antigen-specific immune responses against tumor-associated antigens frequently overexpressed in patients with non-small cell lung cancer; Cas9 mRNA constructs for use in gene editing therapeutics; mRNA based novel therapeutic antibodies; prophylactic vaccines to prevent picornaviruses, influenza, malaria, and rotavirus; and programs against SARS-CoV-2, Lassa virus, and yellow fever. It has strategic partnerships with Genmab, Arcturus, Acuitas, CRISPR Therapeutics, Boehringer Ingelheim, GlaxoSmithKline, the Bill & Melinda Gates Foundation, CEPI, Tesla Grohmann, and others. The company was founded in 2000 and is headquartered in Tübingen, Germany.
| Top 10 Open Interest For Feb 21 Expiration | Top 5 High Yield | |||||
|---|---|---|---|---|---|---|
| 1. | NVDA covered calls | 6. | FXI covered calls | 1. | RGTI covered calls | |
| 2. | TLT covered calls | 7. | TSLA covered calls | 2. | QUBT covered calls | |
| 3. | IWM covered calls | 8. | AMZN covered calls | 3. | DJT covered calls | |
| 4. | SPY covered calls | 9. | ASHR covered calls | 4. | MSTR covered calls | |
| 5. | SLV covered calls | 10. | AAPL covered calls | 5. | SOUN covered calls | |
Want more examples? CUZ Covered Calls | CVBF Covered Calls
